Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Phase II/III Study of Carboplatin Plus Etoposide With AL3810 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

NCT04254471 is registered in ClinicalTrials.gov with Haihe Biopharma Co., Ltd. as lead sponsor.

NCT NCT04254471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04254471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Phase II/III Study of Carboplatin Plus Etoposide With AL3810 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Lead sponsor
Haihe Biopharma Co., Ltd.
Phase
Phase 2/3
Overall status
Unknown status
Start date
November 14, 2019
Completion date
November 22, 2022
Enrollment
313 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small cell lung cancer